Reply to Roesler et al. Comment on “Karaulic et al. Exploring Novel Applications: Repositioning Clinically Approved Therapies for Medulloblastoma Treatment. Cancers 2025, 17, 3659”
Excerpt
We gratefully thank R [...]
Share and Cite
Karaulic, A.; Fournier, C.; Pagès, G. Reply to Roesler et al. Comment on “Karaulic et al. Exploring Novel Applications: Repositioning Clinically Approved Therapies for Medulloblastoma Treatment. Cancers 2025, 17, 3659”. Cancers 2026, 18, 803. https://doi.org/10.3390/cancers18050803
Karaulic A, Fournier C, Pagès G. Reply to Roesler et al. Comment on “Karaulic et al. Exploring Novel Applications: Repositioning Clinically Approved Therapies for Medulloblastoma Treatment. Cancers 2025, 17, 3659”. Cancers. 2026; 18(5):803. https://doi.org/10.3390/cancers18050803
Chicago/Turabian StyleKaraulic, Arthur, Clémence Fournier, and Gilles Pagès. 2026. "Reply to Roesler et al. Comment on “Karaulic et al. Exploring Novel Applications: Repositioning Clinically Approved Therapies for Medulloblastoma Treatment. Cancers 2025, 17, 3659”" Cancers 18, no. 5: 803. https://doi.org/10.3390/cancers18050803
APA StyleKaraulic, A., Fournier, C., & Pagès, G. (2026). Reply to Roesler et al. Comment on “Karaulic et al. Exploring Novel Applications: Repositioning Clinically Approved Therapies for Medulloblastoma Treatment. Cancers 2025, 17, 3659”. Cancers, 18(5), 803. https://doi.org/10.3390/cancers18050803

